PERSEUS: Dara-VRd vs VRd in Patients with NDMM Eligible for Autologous Stem Cell Transplantation
PERSEUS: Daratumumab plus VRd in Newly Diagnosed Multiple Myeloma Patients
Vincent Rajkumar on X: "Impressive results with Dara-VRd in newly diagnosed myeloma presents by Dr. Peter Voorhees. #ASH19. Await phase III PERSEUS. Will consider this regimen for transplant eligible high risk myeloma.
Dara-CVRd, V-ASCT and Dara-Vrd Consolidation in UHiR NDMM and pPCL compared with myeloma XI/XI+ Trial treatment for Uhir MM
Frontiers | Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
Thread by @bdermanmd on Thread Reader App – Thread Reader App
Perseus Study - EMN 17 - Multiple Myeloma Clinical Trials
UK OPTIMUM/MUKnine: Dara-VRd in Ultra-High‒Risk NDMM - Slideset Download - | CCO
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
ASH23: Daratumumab (DARA) + Bortezomib, Lenalidomide, & Dexamethasone (VRd) vs Vrd Alone: Primary Results of the Perseus Trial
ASH23: Perseus Trial: DARA + VRd vs. Vrd Alone in ASCT-Eligible Patients | Pieter Sonneveld, MD, PhD - YouTube
GRIFFIN Update: Dara-R Maintenance - Slideset Download - Hematology 2021 | CCO
Daratumumab plus VRd vs VRd in newly diagnosed MM: GRIFFIN trial 2020 analysis
Treatment approach for transplant ineligible patients. Dara‐VRd,... | Download Scientific Diagram
Phase 3 Perseus Trial in Patients Eligible for ASCT | Int'l Myeloma Fn
Dara-(C)VRd pre- and post-ASCT for ultra-high risk MM and primary plasma cell leukemia
Multiple myeloma with high-risk cytogenetics and its treatment approach | International Journal of Hematology
Vincent Rajkumar on X: "2) VRd is still included as a reasonable alternative for standard risk patients since we do not have data that OS is improved with Dara VRd compared to
Perseus Study - EMN 17 - Multiple Myeloma Clinical Trials
Multiple Myeloma Hub on X: "CONGRESS | #IMW2019 | Peter Voorhees, @levinecancer, presents the GRIFFIN study of dara-VRd in transplant eligible NDMM. Study results suggest Dara-RVd may be a new SOC for
GRIFFIN: VRd ± Dara - Slideset Download - Hematology 2018 | CCO
Aiming for the cure in myeloma: Putting our best foot forward - ScienceDirect
Study design. Abbreviations: VRd: Bortezomib, lenalidomide,... | Download Scientific Diagram
